VanEck Gold Miners ETF vs Medpace Holdings Inc — how do they compare? VanEck Gold Miners ETF trades at $72.1, while Medpace Holdings Inc trades at $535.75 (market cap $15.11B). The key difference: Medpace Holdings Inc is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals.
| GDX | MEDP | |
|---|---|---|
52-Week High | $115.84 | $620.59 |
52-Week Low | $51.15 | $308.88 |
Market Cap | — | $15.11B |
Sector | — | Technology |
Enterprise Value | — | $14.58B |
Signals from Pluang's Aura AI — not financial advice
The VanEck Gold Miners ETF (GDX) is trading at $71.97, down 3.89% over the past 24 hours, with a strong bearish technical signal from moving averages. The fund provides exposure to senior gold mining equities, which are currently trading at historically low valuations according to recent analysis, with forward P/E and EV/EBITDA multiples at five-year lows. Recent news highlights ongoing comparisons with lower-fee bullion ETFs and debates about the optimal vehicle for gold exposure.
The outlook presents a dichotomy: attractive valuation metrics and record free cash flow yields suggest potential upside if gold prices rally, while technical weakness and competition from more efficient gold ETFs pose significant risks. A re-rating to historical valuation norms could imply 20% upside, but the fund's performance remains heavily dependent on gold price movements and mining company operational execution.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →